Yesterday Teva presented its Q1'25 results, with Uzedy sales for the quarter coming in at USD39m (+160% YoY). While beating Teva's css (USD32.5m, +20%), sales appeared relatively flattish compared Q4 (USD43m), which could be attributed to calendar effects and stock adjustments. We remain optimistic
Interparfums has reported 10.7% sales growth for Q1 (+8% at same FX). The fragrance market remained strong, including in the US. Since the beginning of April, momentum has been less dynamic and more volatile. Nevertheless, the group's management reiterated FY sales guidance (EUR930m to EUR935m). We
MedinCell and iM4TB to initiate the development of a LAI version of Macozinone for the treatment of tuberculosis, a potential first-in-class which has shown promising results in past phase 1/2 studies. The value add of a long-acting formulation in tuberculosis is clear, considering that current tre
A director at TUI AG bought 4,000 shares at 6.070EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...
Teva presented early clinical feedback from a patient and healthcare professional survey regarding its olanzapine LAI TEV'749 (mdc-TJK), in particular around important schizophrenia treatment factors — dosing schedule, initiation regimen, SC administration, post-injection monitoring requirements an
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.